Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: Implications for immunogenicity in dendritic cell-based immunotherapy

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Chung, David J ^a,c,d,e,f   Romano, Emanuela ^a,e,g   Pronschinske, Katherine B ^a,e   Shyer, Justin A ^a,e   Mennecozzi, Milena ^b,e,h   Angelo, Erin T St ^a,e   Young, James W ^a,c,d,e,f  

^a Laboratory of Cellular Immunobiology   (United States)

^b Swim Across America Laboratory   (United States)

^c Bone Marrow Transplant Service   (United States)

^d Department of Medicine ^*  (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h JOINT RESEARCH CENTRE   (Italy)

Author keywords

Cancer; Dendritic cells; Immunotherapy; mRNA electroporation

Indexed keywords

CD34 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ASSAY; CELL LOSS; CELL MATURATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; LANGERHANS CELL; LYMPHOCYTE PROLIFERATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; T LYMPHOCYTE; TRANSGENE;

ANTIGEN PRESENTATION; CELL SURVIVAL; CYTOKINES; DENDRITIC CELLS; ELECTROPORATION; GENETIC PREDISPOSITION TO DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; ISLETS OF LANGERHANS; MONOCYTES; PHENOTYPE; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSGENES;

EID: 84879999671     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-166     Document Type: Article

References (26)

1. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667. 10.1146/annurev.immunol.20.100301.064828, 11861614.
2. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104:2235-2246. 10.1182/blood-2003-12-4392, 15231572.
3. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277. 10.1038/nrc3258, 3433802, 22437871.
4. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. NatBiotech 1998, 16:364-369.
5. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000, 164:5508-5514.
6. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001, 61:3388-3393.
7. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409-417. 150859, 11828001.
8. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001, 98:49-56. 10.1182/blood.V98.1.49, 11418462.
9. Tuyaerts S, Michiels A, Corthals J, Bonehill A, Heirman C, de Greef C, Noppe SM, Thielemans K. Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther 2003, 10:696-706. 10.1038/sj.cgt.7700622, 12944989.
10. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003, 101:977-982. 10.1182/blood-2002-04-1273, 12393470.
11. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010, 107:13824-13829. 10.1073/pnas.1008051107, 2922237, 20631300.
12. Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchock JD, Houghton AN, Chapman PB, Heller G, et al. Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo. Clin Cancer Res 2011, 17:1984-1997. 10.1158/1078-0432.CCR-10-3421, 21355077.
13. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004, 199:251-263. 10.1111/j.0105-2896.2004.00139.x, 15233739.
14. Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL, Munz C, Heller G, Young JW. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic. cells J Immunol 2004, 173:2780-2791. Erratum in J Immunol. 2005; 2174:3818.
15. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29:497-510. 10.1016/j.immuni.2008.07.013, 2688399, 18789730.
16. Romano E, Cotari JW, Barreira DaSilva R, Betts BC, Chung DJ, Avogadri F, Fink MJ, St Angelo ET, Mehrara B, Heller G, et al. Human Langerhans cells use an IL-15R-alpha/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood 2012, 119:5182-5190. 10.1182/blood-2011-09-382200, 3369609, 22510877.
17. Banchereau J, Thompson-Snipes L, Zurawski S, Blanck J-P, Cao Y, Clayton S, Gorvel J-P, Zurawski G, Klechevsky E. The differential production of cytokines by human Langerhans cells and dermal CD14+ DCs controls CTL priming. Blood 2012, 119:5742-5749. 10.1182/blood-2011-08-371245, 3382933, 22535664.
18. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005, 12:772-782. 10.1038/sj.gt.3302471, 15750615.
19. Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, Wesenberg F, Gaudernack G. Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia. BMC Cancer 2005, 5:20. 10.1186/1471-2407-5-20, 554108, 15720715.
20. Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol 2005, 139:458-467. 10.1111/j.1365-2249.2005.02733.x, 1809302, 15730391.
21. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 2000, 7:2028-2035. 10.1038/sj.gt.3301326, 11175315.
22. Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009, 11:653-668. 10.1080/14653240902960411, 19530029.
23. Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med 2006, 4:35. 10.1186/1479-5876-4-35, 1570143, 16911798.
24. Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlovic S. Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 2004, 6:563-570. 10.1080/14653240410005357-1, 15773024.
25. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61:6451-6458.
26. Munz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005, 105:266-273. 10.1182/blood-2004-06-2492, 15331446.